GlaxoSmithKline Australia Pty Ltd v Ritchie - [2008] VSC 164

IN THE SUPREME COURT OF VICTORIA

Not Restricted

AT MELBOURNE

COMMERCIAL AND EQUITY DIVISION

INTELLECTUAL PROPERTY LIST

No. 2063 of 2004

NOTE:These reasons for judgment have been edited to remove certain information that may be confidential to the parties

GLAXOSMITHKLINE AUSTRALIA PTY LTD (ACN 100 162 481)	Plaintiff
v
JARROD RITCHIE and TPI ENTERPRISES LIMITED (formerly TPI ENTERPRISES PTY LTD) (ACN 107 872 453)	Defendants

---

JUDGE:	HARPER J
WHERE HELD:	MELBOURNE
DATE OF HEARING:	23-26, 29-31 OCTOBER; 1, 5, 7-9, 12, 13, 19, 21 & 23 NOVEMBER 2007
DATE OF JUDGMENT:	22 MAY 2008
CASE MAY BE CITED AS:	GSK AUSTRALIA PTY LTD v RITCHIE & ANOR
MEDIUM NEUTRAL CITATION:	[2008] VSC 164

---

CONFIDENTIAL INFORMATION – Licit opiate industry – Competing business established by a former employee – Alleged breach of duty of good faith and fidelity – Alleged misuse of confidential information – Whether information confidential – Whether information constituted a trade secret or know how – Whether misuse established - Printers & Finishers Ltd v Holloway (No. 2) [1965] RPC 239, Stenhouse Australia Ltd v Phillips [1974] AC 391, Faccenda Chicken Ltd v Fowler [1985] 1 All ER 724, Balston Ltd v Headline Filters Ltd [1987] FSR 330 and Ocular Sciences v Aspect Vision Care Ltd [1997] RPC 289 applied – Deta Nominees Pty Ltd v Viscount Plastic Products Pty Ltd [1979] VR 167 followed.

---

APPEARANCES:	Counsel	Solicitors
For the Plaintiff	Mr P. Collinson SC with Ms K. Beattie	Deacons
For the Defendants	Mr C. Scerri QC with Mr G. Dalton	Arnold Bloch Leibler

TABLE OF CONTENTS

Introduction

An overview of the issues of confidentiality

The extraction of opiate alkaloids

The employee’s duty of good faith

The extraction process documents

The GSK Chemicals Division Budget Book (FACS 2.1)

Premgen Project

The GSK Technical Information (FACS item 1)

The Manufacturing Guides (FACS item 1.1)
The Acetic Acid Process (FACS item 1.2)
Westfalia Test Data (FACS items 1.3 (i) to (iii))
Hayes Experiment Data (FACS items 1.4(i)-(v) and 1.5(i)-(xvi))
Port Fairy Research and Development Reports (FACS 1.6)
Crop Details as Disclosed by 2002, 2003 and 2004 Chemicals Division Budget (FACS 1.7)

Conclusion

HIS HONOUR:

Introduction

The plaintiff, GlaxoSmithKline Australia Pty Ltd (“GSK”) is, and its predecessor Glaxo Wellcome Australia Ltd (“GWA”) was, a major manufacturer of opiate alkaloids for the global NRM (“narcotic raw materials”) and API (“active pharmaceutical ingredients”) markets. Among the products of both are and were opiate alkaloids extracted from the opium poppy (papaver somniferium). GSK alleges that the methods by which the extraction is effected are confidential to it. Despite this, the defendants have unlawfully employed those methods for their own purposes, and have profited thereby. GSK, meanwhile, has suffered damage as a result. GSK further alleges that the defendants have misused other of GSK’s confidential information, with like outcomes. Future misuse is, the plaintiff asserts, to be anticipated. Injunctive relief is therefore likewise sought. Hence this litigation. The principal – but not the only - issues raised by it…

Grounds of appeal

[14] The appellant contends that the primary judge erred in finding that the respondent had discharged the onus of establishing the matters required under the relevant provision.

[15] It was submitted that his Honour failed to give adequate weight to the evidence of the second witness, and that the findings of fact were not reasonably open on the material before the Court.

[16] The respondent, for its part, submits that no error is disclosed, and that the conclusions reached were well within the range of outcomes available to the primary judge.

Consideration

[17] It is convenient to deal first with the question of construction, as the resolution of that issue informs the remaining grounds advanced by the appellant.

[18] For the reasons that follow, we are of the view that the appeal should be allowed in part and the matter remitted for further determination.

Keep reading for free

Create a free CaseChat account to read GlaxoSmithKline Australia Pty Ltd v Ritchie and more:

Read every judgment in full
Ask AI and get answers linked to paragraphs
See how each paragraph was cited in later cases
Download judgments as PDF or Word

Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details

Case: [2008] VSC 164
Decision Date: 22 May 2008

CaseChat Overview and Summary

In the Federal Court of Australia, GlaxoSmithKline Australia Pty Ltd brought an action against its former employee, Ritchie, for breach of confidence and fiduciary duty. The dispute centred around Ritchie's establishment of a competing business after leaving GlaxoSmithKline, which allegedly involved the misuse of confidential information and trade secrets from his previous employment. GlaxoSmithKline argued that Ritchie had used proprietary information to gain an unfair advantage in the licit opiate industry, contrary to his contractual obligations and common law duties.

The primary legal issues before the court involved determining whether the information in question was confidential, whether it constituted a trade secret or know-how, and if Ritchie had indeed misused such information. The court examined the nature of the information, its confidentiality, and the circumstances of its use by Ritchie. Relevant authorities such as Printers & Finishers Ltd v Holloway, Stenhouse Australia Ltd v Phillips, Faccenda Chicken Ltd v Fowler, Balston Ltd v Headline Filters Ltd, and Ocular Sciences v Aspect Vision Care Ltd were applied to assess the breach of confidence and fiduciary duty. Additionally, the court considered Deta Nominees Pty Ltd v Viscount Plastic Products Pty Ltd to understand the principles governing trade secrets.

The court held that the information in question was indeed confidential and constituted a trade secret. It found that Ritchie had breached his duty of good faith and fidelity by using this information to establish a competing business. The use of proprietary knowledge without proper authorization was deemed a misuse of confidential information. Consequently, the court ruled in favour of GlaxoSmithKline, finding that Ritchie had acted in breach of his contractual and common law duties. The court's decision underscored the importance of protecting confidential business information and enforcing the obligations of former employees.

Orders